”Small Molecule API Contract Manufacturer Quality Benchmarking (2016)” — quality benchmarking reports now available
Suite of reports provide readers with a comprehensive assessment of biopharmaceutical CMO service quality across three key areas of outsourced manufacturing: small molecule, biologic and fill finish.
Industry Standard Research (ISR) has announced the addition of three reports to its Contract Manufacturer Quality Benchmarking suite of reports to provide readers a comprehensive assessment of biopharmaceutical CMO service quality across three key areas of outsourced manufacturing: small molecule, biologic and fill finish. As biopharma companies continue to increase their levels of external development and manufacturing, the need for unbiased information to support strategic business decisions remains critical.
These reports provide a Consumer Reports-style analysis where each of the 83 CMOs included in the research was evaluated across 26 service quality attributes, making these reports the most comprehensive assessment of quality in the contract manufacturing space. These 26 attributes were categorized into four 'scorecards': Delivery Factors, Organization Factors, Capabilities, and Staff Characteristics. Respondents were asked to recall their specific experiences working with the manufacturers, and to indicate how well the manufacturer(s) performed with respect to expectations. For buyers of outsourced services, the report includes highly valuable information to help guide CMO selection for small molecule, biologic or fill finish projects from early clinical stages to commercialization.
"There has been a tendency to conflate CMOs' service offerings when it comes to performance evaluations, especially in syndicated research," explained Kate Hammeke, Director of Market Research at Industry Standard Research. "That approach makes it easier to acquire the desired sample size to conduct an analysis, but the insights lack the depth of information both sponsors and contract manufacturers crave. Starting this year, ISR's Contract Manufacturer Quality Benchmarking research has been split into three tracks of data collection, enabling sponsors to evaluate CMOs on specifics related to the type of project for which the CMO was engaged, whether it was for small molecule API, biologic API or fill finish. This depth of information and audience-actual customers who have worked with the CMO in the past 18 months-has previously only been available through custom market research."
CMO performance attributes evaluated by respondents include Reliable on-time delivery, Regulatory History, Quality performance metrics, Scale-up and tech transfer abilities, Scientific knowledge, Right-first-time measurements, and many others.
The reports include data on 83 different contract manufacturing organizations, including: 3M Drug Delivery Systems, AAI/Cambridge Major, AbbVie Contract Manufacturing, Aenova, Aeras CMO, Aesica, AMRI, Albemarle, Almac, Althea, AMPAC Fine Chemicals, Aptuit, Ash Stevens, Avid Bioservices, Baxter BioPharma Solutions, BioReliance, Boehringer Ingelheim, Cambrex, Capsugel, Catalent, Celltrion, Chartwell Pharmaceuticals, CMC Biologics, Cobra Biologics, Cook Pharmica, Corden Pharma, CoreRx, CPL, Cytovance Biologics, Dalton Pharma Services, DPT, Dr. Reddy's CPS, Ei, Emergent Biosolutions, Evonik, Fareva, Flamma, FujiFilm Diosynth Biotechnologies, Glatt Pharmaceutical Services, GSK Contract Manufacturing, Halo Pharma, Helsinn, Hetero, Hospira One2One, Hovione, IDT Biologika, Jubilant HollisterStier, KBI Biopharma, Kemwell, Lonza, Metrics, Neuland, NextPharma, Norwich, Novasep, Paragon, Patheon, PCI Synthesis, Pfizer CentreSource, PharmaCore, Pharmatek, PharmaZell, Pii, Piramal Pharma Solutions, Recipharm, Rentschler, Richter-Helm, Rottendorf Pharma, SAFC, SAI Life Sciences, Samsung BioLogics, Sandoz, Sanofi CEPiA, Siegfried, Symbiosis, Therapure BioPharma, Unither Pharamceuticals, UPM Pharmaceuticals, Vetter, WellSpring, Wockhardt, Xcelience.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance